FMC CORP (FMC)

FMC Corp shares closed at $4.78, up 7.17% on volume of 8.9 million shares, despite a series of bearish earnings disclosures. The company reported a third-quarter adjusted EPS loss of $4.41 and sales of $105.9 million, both far below analyst estimates of $0.10 per share and $859.594 million. FMC also slashed its full-year 2026 adjusted EPS outlook to a loss of $3.66-$3.50 from $1.19-$1.49 and cut its 2026 sales outlook to $2.750-$2.850 billion from $3.500-$3.700 billion, while trimming its fourth-quarter adjusted EPS forecast to $0.56-$0.70 from $1.09-$1.33. The stock rose even as these high-impact bearish earnings revisions pointed to deteriorating fundamentals, suggesting the market may have already priced in much of the bad news or was reacting to the Form 8-K filing on a major company event.

FMC shares closed at $5.66, up 3.76% on heavy volume of over 15.2 million shares, despite a wave of bearish analyst actions. Barclays maintained an Underweight rating and lowered its price target to $4, BMO Capital kept Market Perform while cutting its target to $7.5, and Jefferies downgraded the stock to Hold with a $5 target. Additionally, an analyst warned that FMC's dividend could be the next casualty as a pesticide price war deepens. Although the stock rallied today, the cluster of downgrades and dividend concerns suggests continued downward pressure.

FMC Corporation shares closed at $5.62, up 9.77% on heavy volume of over 25 million shares, despite a wave of bearish news. The company slashed its Q3 revenue outlook to just $65M-$125M with adjusted EBITDA of negative $565M to negative $510M, and warned that commercial actions will result in $625 million to $675 million in charges. RBC Capital maintained a Sector Perform rating but lowered its price target to $9. Although the stock rallied sharply, the underlying news remains highly negative, with the earnings warning and downgrade suggesting continued downside risk.